A tough year 10 December 2025

https://rarerevolutionmagazine.com/a-tough-year/ Nicola Redfern is back with her final Industry Insights for 2025. In a year that was tough for biotech and pharma, with policy uncertainty and negotiations slowing access to rare disease innovations, 2026 offers hope with MHRA-NICE collaboration, new rare disease models, and higher NICE thresholds.